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ABSTRACT 
The incidence of cholangiocarcinoma (CCA) has risen in many countries, but there is still no appropriate screening 
and treatment available. The growing number of microarray data published todays can be a powerful resource for 
the discovery of biomarkers to tackle challenges in the management of CCA. This study analyzed multiple micro-
array datasets to identify the common transcriptional networks in CCA and select a possible biomarker for func-
tional study in CCA cell lines. A systematic searching identified 4 microarray datasets from Gene Expression 
Omnibus (GEO) repository and PubMed articles .Differential expression analysis between tumor and normal tis-
sues was performed in each dataset. In order to characterize the common expression pattern, differentially ex-
pressed genes (DEGs) from all datasets were combined and visualized by hierarchical clustering and heatmap. 
Gene enrichment analysis performed in each cluster revealed that over-expressed DEGs were enriched in cell 
cycle, cell migration and response to cytokines while under-expressed DEGs were enriched in metabolic processes 
such as oxidation-reduction, lipid, and drug. To explain tumor characteristics, genes enriched in cell migration and 
response to cytokines were further investigated. Among these genes, CCL20 was selected for functional study 
because its role has never been studied in CCA. Moreover, its signaling may be regulated by disrupting its only 
receptor, CCR6. Treatment with recombinant CCL20 induced higher cell migration and increased expression of 
N-cad. In contrast, knockdown of CCR6 by siRNA reduced cell migration ability and decreased N-cadherin level .
Altogether, these results suggested the contribution of CCL20/CCR6 signaling in cell migration through epithelial-
mesenchymal transition process. Thus, CCL20/CCR6 signaling might be a target for the management of CCA. 
 
Keywords: CCL20, CCR6, cholangiocarcinoma (CCA), microarray, epithelial-mesenchymal transition (EMT), 
cell migration 
 
 
INTRODUCTION 
Cholangiocarcinoma (CCA), the primary 
cancer of bile duct epithelium, has a high in-
cidence rate in Thailand but is rare in other 
parts of the world (Kirstein and Vogel, 2016). 
Interestingly, its incidence in many parts of 
the world has increased (Khan et al., 2019; 
Patel and Benipal, 2019). Chronic infection 
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with the liver fluke, Opisthorchis viverrini, is 
the major risk factor for the development of 
CCA in northeast Thailand (Sripa et al., 
2007). Abnormal growth and the accumula-
tion of genetic and epigenetic aberrations 
eventually result in malignant transformation 
of the bile duct epithelium (Sripa et al., 2007). 
The morbidity and motility rate of this disease 
is high because of its late clinical presentation 
(Goral, 2017). Currently, the most effective 
treatment is tumor resection. Nevertheless, 
patients with advanced cancer might not be 
eligible for this treatment (Wu et al., 2019). 
Early diagnosis and a more effective thera-
peutic approach remain a major challenge for 
CCA. 
High throughput technology, such as mi-
croarray, has been used for decades. Several 
biomarkers have been identified since then 
contributing to a better understanding and 
management of either physiological or patho-
logical conditions (Butler et al., 2017; 
Mazandu et al., 2017). Continuous improve-
ment in bioinformatics enables scientists to 
gain more insight from their data (Mack et al., 
2014). Compared to the classical research de-
sign that focuses on evaluating a particular set 
of genes or molecules, a data-driven and hy-
pothesis-free method analyzes all possible 
targets available in the sample to elucidate the 
global mechanism of the disease and facilitate 
the less biased approach for biomarker dis-
covery.  
Given the availability of microarray data 
from Gene Expression Omnibus (GEO) data-
base, this work revisited and selected differ-
entially expressed genes (DEGs) from multi-
ple microarray datasets. Chemokine (C-C mo-
tif) ligand 20 (CCL20), which was over-ex-
pressed in CCA and enriched in cell migration 
and response to cytokine networks, was se-
lected for functional study. Its role has been 
demonstrated in many cancers including 
breast cancer and colorectal cancer (Xu and 
Pasche, 2007; Marsigliante et al., 2016). Its 
contribution to epithelial-mesenchymal trans-
ition (EMT) process, a major mechanism of 
cancer migration, has been also demonstrated 
(Katsuno et al., 2013; Hou et al., 2015). How-
ever, the role of CCL20 in CCA remains un-
known. Thus, this work examined the expres-
sion of CCL20 and its receptor, CCR6, and 
investigated their function in CCA cell lines. 
 
MATERIALS AND METHODS 
Selection of microarray dataset 
Microarray data were identified in the 
GEO (https://www.ncbi.nlm.nih.gov/geo/) 
and PubMed (https://www.ncbi.nlm.nih.gov 
/pubmed/) databases on April 6, 2017 by us-
ing keywords “Cholangiocarcinoma” and 
“Cholangiocarcinoma AND Expression pro-
filing”, respectively (Figure 1). Human 
(Homo sapiens) tissue sample was used as the 
initial inclusion criterion for search results in 
GEO. In PubMed, the GEO dataset accession 
number must be provided and microarray ex-
periment must be performed in humans. The 
following exclusion criteria were used for re-
moving the remaining datasets: miRNA ex-
pression profile, methylation microarray, cell 
line or tissue culture, biliary stricture samples, 
and the number of normal tissues was less 
than 10 % of the sample size. 
 
Microarray data analysis and gene enrich-
ment analysis 
Data were inspected and evaluated the re-
quirement for the additional pre-processing 
step. If needed, pre-processing in each dataset 
was performed separately by using “limma” 
package from R/Bioconductor (Ritchie et al., 
2015; Zhong et al., 2018). In general, the pre-
processing step includes target file reading, 
background correction, data normalization, 
removal of control and low quality probes, 
and log2 transformation were performed. The 
data sets GSE26566, GSE32879, GSE45001, 
and GSE57555 retained 22182, 18308, 17812 
and 19624 probes respectively after pre-pro-
cessing. Unsupervised analysis and outlier de-
tection was performed by using principal 
component analysis (PCA). DEGs (false dis-
covery rate; FDR <0.05) between tumor and 
normal tissue for each dataset were identified 
by using “limma” method. Fold-change (FC) 
was calculated between the average intensity
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Figure 1: Selection of microarray datasets and identification of DEGs. Datasets in GEO and PubMed 
were identified by the indicated keywords. The number of datasets identified by each keyword was 
shown in the corresponding parenthesis. Four datasets were selected in the final step based on the 
exclusion criteria. GEO accession number, microarray platform, number of tumor and normal tissues, 
and the reference for each of these datasets are listed. DEGs obtained from each dataset were com-
bined (n = 13649). DEGs that were over- or under-expressed in at least 3 datasets (n = 2899) were 
selected for the downstream analysis. 
 
 
of tumor and normal samples. Gene symbol 
was used to map and combine FC values from 
each dataset. FC of 1 was assigned for a miss-
ing value. In case of a duplicated gene sym-
bol, the probe with higher intensity was used 
as the representative of that gene symbol. 
DEGs with FC of at least  1.5 in at least 3 
datasets were selected and visualized by un-
supervised hierarchical clustering heatmap to 
discover the common expression pattern 
across all datasets. Dendrogram was cut ac-
cording to tree height. Gene network analysis 
was performed by STRING (https://string-
db.org/). Enriched biological processes with 
FDR<0.05 were reviewed. 
Cell line and cell culture 
Human CCA cell lines HuCCT1 and 
TFK-1 were purchased from the RIKEN BRC 
(Ibaraki, Japan). Cells were cultured in 
RPMI-1640 (Gibco, NY) with 10 % fetal bo-
vine serum (FBS) (Gibco, NY) and 100 U/mL 
penicillin and 100 µg/mL streptomycin 
(Invitrogen, MA) and incubated at 37 °C in a 
5 % CO2 humidified atmosphere. 
 
RNA isolation and real-time reverse tran-
scriptase polymerase chain reaction (RT-
PCR) 
Total RNA was isolated using Vivantis 
GF-1 Total RNA Extraction Kit (Vivantis 
Technologies, Malaysia) according to the 
manufacturer’s protocol. One µg of RNA was 
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converted to cDNA with the Mastercycler 
Nexus GX2 (Eppendorf, Germany) using iS-
cript cDNA Synthesis Kit (Bio-Rad, CA) ac-
cording to the manufacturer’s protocol. Quan-
titative PCR reaction was prepared using Sso-
Fast Evagreen (Bio-Rad, CA, USA) in con-
junction with specific primers as follows: 
CCL20 forward 5’-CAA CTT TGA CTG 
CTG TCT TGG AT-3’ and reverse 3’-ACT 
TTT TTA CTG AGG AGA CGC AC-5’, 
CCR6 forward 5’-TGC TCT ACG CTT TTA 
TTG GG-3’ and reverse 3’-TTG TCG TTA 
TCT GCG GTC TC-5’ and GAPDH forward 
5’-GTG GAC CTG ACC TGC CGT CT-3’ 
and reverse 3’-TGT CGC TGT GGG TGA 
GGA GG-5’. The reaction was performed 
through CFX96 Real-Time Thermocycler de-
tection system (Bio-Rad, CA) including ini-
tial denaturation at 95 °C for 30 seconds, fol-
lowed by 40 cycles of denaturation at 95 °C 
for 30 seconds and annealing/extension at 
60 °C for 5 seconds. Melt curve analysis was 
performed at 65 °C to 95 °C. Relative quanti-
tative expression is calculated by means of 
fold change (∆Ct) after normalizing with the 
reference gene GAPDH. The experiment was 
carried out in three independent sets. 
 
Knockdown of CCR6 
Reverse transfection was carried out using 
Lipofectamine® 3000 (Thermofisher Scienti-
fic, CA) according to the manufacturer’s pro-
tocol. Briefly, 15 pmol negative control 
siRNA (Silencer Select Negative Control 
No.1 siRNA, Thermo Scientific, CA) or 
CCR6 siRNA (siCCR6, s3214, Thermo Sci-
entific, CA) was diluted in serum-free Opti-
MEM medium (Thermo Scientific, CA). Di-
luted siRNA was incubated at the ambient 
temperature for 5 minutes before the addition 
of Lipofectamine® 3000. The complex was 
incubated at the ambient temperature for 20 
minutes and transferred to cell suspended in 
an antibiotic-free medium. Transfected cells 
were incubated at 37 °C for 12-16 h until the 
cells were completely attached to the plate. 
The RPMI-1640 medium containing 5 % FBS 
was replenished. The transfection was incu-
bated for 24 h until used in the subsequent ex-
periment. 
 
Western blot analysis 
Total protein was extracted by RIPA lysis 
buffer (Cell Signaling Technology, MA) con-
taining protease inhibitor cocktail (Cell Sig-
naling Technology, MA). Protein concentra-
tion was measured by Bradford protein assay 
(Bio-Rad, CA). Cell lysate in the amount of 
15 µg (for all proteins) or 50 µg (for N-cad 
detection in TFK-1) was loaded onto 10 % so-
dium dodecyl sulfate-polyacrylamide gel 
electrophoresis and transferred onto nitrocel-
lulose membrane (Bio-Rad, Germany). The 
membrane was blocked with 5 % skim milk 
and later probed overnight at 4 °C with pri-
mary antibodies including 1:1000 mouse anti-
human CCR6 (14-1969-82, Thermo Fisher 
Scientific, CA), 1:10000 rabbit anti-human α-
tubulin (2144, Cell Signaling Technology, 
MA), 1:5000 rabbit anti-human E-cadherin 
(3195, Cell Signaling Technology, MA), 
1:5,000 rabbit anti-human N-cadherin 
(13116, Cell Signaling Technology, MA), 
1:5,000 rabbit anti-human β-actin (4967, Cell 
Signaling Technology, MA). The membrane 
was washed 3 times and probed with appro-
priate secondary antibody including goat 
1:20,000 anti-mouse-horseradish peroxidase 
(626520, Invitrogen, MA) and 1:5,000 goat 
anti-rabbit-horseradish peroxidase (7074, 
Cell Signaling Technology, MA). The chem-
iluminescence intensity was measured by 
ECL Western blotting detection (GE 
Healthcare, UK) under Gel DocTM XP+ Gel 
Documentation System equipped with Image 
LabTM Software version 6.0.0 (Bio-Rad, CA). 
The experiment was carried out in three inde-
pendent sets. 
 
Wound healing assay  
Cells seeded in 12-well plate were incu-
bated until it reaches 90 % confluency. The 
cell monolayer was scratched with a yellow 
pipette tip. The wound area was photographed 
at 0, 6, 9 and 12 h under the light microscope 
and measured by ImageJ software version 
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1.8.0 (National Institutes of Health, USA). 
Relative wound area compared to 0 h was cal-
culated. The experiment was carried out in 
three independent sets. 
 
Cell proliferation (MTS) assay  
HuCCT1 cells were transfected with 
siRNA in 96-well plate and incubated for 12 
h. The medium was replaced with RPMI-
1640 supplemented with 10 % FBS and fur-
ther incubated for 24, 30 and 36 h followed by 
the addition of CellTiter 96 Aqueous One so-
lution (Promega, WI). The reaction was incu-
bated for 2 h and the absorbance at 490 nm 
was measured by Synergy HTX multi-mode 
reader (BioTek, VT). The assay was per-
formed in three independent sets of triplicate 
wells. 
 
Cell migration assay 
HuCCT1 cells were transfected with 
siRNA for 24 h before collected by trypsini-
zation. TFK-1 were collected directly without 
siRNA transfection. 1.5 x 105 cells were re-
suspended in a FBS free-RPMI-1640 and 
plated inside the Transwell insert (Corning In-
corporated, NY). The lower chamber contain-
ing a RPMI-1640 supplemented with 5 % 
FBS or 5 % FBS with recombinant CCL20 
(rCCL20, Thermo Fisher Scientific, CA). Af-
ter 12 h (HuCCT1) or 16 h (TFK-1) incuba-
tion at 37 °C, non-migrated cells inside the 
upper membrane were removed by cotton 
swab and washed twice with phosphate buff-
ered saline. The membrane was fixed with ab-
solute ethanol for 10 minutes at room temper-
ature and stained with 0.5 % crystal violet. 
The number of migrated cells was counted 
from 10 randomly selected areas. The number 
of migrated cells in relation to the respective 
control was calculated. The experiment was 
carried out in three independent sets. 
 
Statistical analysis 
Statistics analysis was performed using 
student’s t test from GraphPad Prism 7 
(GraphPad Software, CA). The p-value of 
< 0.05 was considered statistically signifi-
cant.  
 
RESULTS 
Over-expression of cell cycle and cell  
migration and under-expression of  
metabolic processes were common in CCA 
datasets  
Microarray datasets were searched and se-
lected from both GEO repository and PubMed 
literature to include as much as possible all 
available datasets (Figure 1). After a system-
atic selection, 4 datasets were identified in-
cluding 2 datasets from GEO searching, 
GSE45001 (Sulpice et al., 2016) and 
GSE57555 (Murakami et al., 2015), and 2 da-
tasets from PubMed searching, GSE26566 
(Andersen et al., 2012) and GSE32879 (Oishi 
et al., 2012). All of these microarray datasets 
were obtained from CCA tissues and a mini-
mum sample size of 10 % non-tumor tissues.  
Differential expression analysis between 
tumor and normal tissues identified a total of 
13649 unique DEGs including 1988, 2895, 
12110, and 6464 from GSE45001, 
GSE57555, GSE26566 and GSE32879, re-
spectively. 2899 DEGs were selected by fil-
tering with an average fold-change of  1.5 in 
at least 3 datasets, of which 1610 were over-
expressed and 1289 were under-expressed 
(Figure 2). The heatmap shows consistent 
trends in the expression of these DEGs in all 
datasets. As expected, DEGs were separated 
into clusters of over-expression (O) and un-
der-expression (U). To aid the gene enrich-
ment analysis, we further divided these major 
clusters into 5 (O1 – O5) and 5 (U1 – U5) sub-
clusters, respectively (Supplementary Figure 
1 and Supplementary Table 1).  
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Figure 2: Expression profile of 2899 DEGs across 4 datasets and gene network analysis for DEGs in 
cluster O5. Right panel: Hierarchical clustering of 2899 DEGs with 1.5-fold over- or under-expressed in 
at least 3 datasets. Rows are DEGs and columns are datasets. Blue and red indicate under- and over-
expression in CCA relative to their non-tumor tissues. Cluster ID and its number of DEGs were shown 
on the right of the heatmap: O, over-expressed (orange) and U, under-expressed (green) cluster. The 
enclosed area indicates subcluster O5, the uniformly over-expressed DEGs across all 4 datasets. Left 
panel: Gene network analysis for cluster O5. Nodes are color coded as followed: red, cell migration; 
cyan, response to cytokine; yellow, development of blood vessel; and blue, cell cycle. The location of 
CCL20 was zoomed in and shown in the square at the top of the network. 
 
 
Gene enrichment analysis was performed 
for each subcluster. Due to a large number of 
significantly enriched biological processes 
(FDR < 0.05) and redundancy of gene ontol-
ogy terms, manual reviewed was performed 
on enriched processes. Networks, which 
cover high percentage of gene list were con-
sidered the representative of enriched net-
works for each subcluster. After overall anal-
ysis, we found that cell cycle, cell migration, 
response to cytokine and blood vessel devel-
opment were the common enriched biological 
processes for subclusters O1 to O5. While li-
pid metabolic process, drug metabolic pro-
cess, blood coagulation and regulation of 
complement activation were commonly en-
riched for each subclusters U1 to U5 (Table 
1). Based on this result, over-expressed genes 
might play an important role for cancer char-
acteristics such as cell cycle and cell migra-
tion. Therefore, genes in cluster O5 were con-
sidered for subsequent analysis because of 
their highest magnitude of over-expression. 
To link to the tumor microenvironment, genes 
in networks of cell migration and response to 
cytokine were reviewed. Ten genes including 
ADAM9, CCL20, COL1A1, COL1A2, 
CXCL5, FOXC1, LEF1, MIF1, MMP1, and 
WNT5A were enriched in both cell migration 
and response to cytokine. Among these genes, 
the role of CCL20 has not been studied in 
CCA. Moreover, this chemokine has only one 
specific receptor CCR6, their specific effect 
in CCA might be investigated by modulating 
their interaction. Therefore, CCL20 and 
CCR6 were chosen for functional validation 
in our study. 
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Table 1: Size and the enriched biological processes in each subcluster 
A. Over-expressed DEGs 
Cluster #Gene Cell cycle Migration Cytokine Blood vessel 
O1 447 35 45 43 28 
O2 294 0 0 0 0 
O3 273 35 23 26 17 
O4 138 0 0 0 0 
O5 458 66 55 41 20 
Total 1610 136 123 110 65 
B. Under-expressed DEGs 
Cluster #Gene Oxidation-reduction Lipid Drug Small molecule 
U1 244 56 55 46 106 
U2 204 36 38 0 58 
U3 278 39 37 0 67 
U4 345 72 68 43 119 
U5 218 55 66 47 91 
Total 1289 258 264 136 441 
 
 
 
Expression of CCL20/CCR6 and the EMT 
markers in CCA cell lines 
To investigate the role of CCL20 and 
CCR6 in CCA, mRNA expression of these 
genes were screened in HuCCT1 and TFK-1 
cells using real-time RT-PCR. As shown in 
Figure 3a, different expression levels of 
CCR6 and CCL20 was observed in these cell 
lines. Markedly high CCL20 expression was 
observed in HuCCT1, while the expression of 
both genes was comparable in TFK-1. Next, 
we examined the role of CCL20 in EMT pro-
cess. The constitutive expression of both E-
cadherin (E-cad) and N-cadherin (N-cad) was 
detected in HuCCT1 with 15 g of protein 
used in Western blot assay, whereas only E-
cad could be detected in TFK-1 (Figure 3b). 
Nevertheless, it was possible to detect N-cad 
with 50 g cell lysate in TFK-1 (see Figure 
5c). Altogether, the results highlighted the 
difference in expressions of CCL20 and EMT 
markers in HuCCT1 and TFK-1. Constitutive 
expression of CCL20 in HuCCT1 may be re-
sponsible for its higher expression of mesen-
chymal markers such as N-cad. To further 
validate the involvement of CCL20/CCR6 in 
EMT process, CCA cell lines were treated 
with siCCR6 or rCCL20 and migration assays 
were performed.  
 
siCCR6 transfection in HuCCT1 and  
TFK-1 
CCR6 knockdown assays were performed 
in both HuCCT1 and TFK-1. Western blot 
analysis showed a decrease in CCR6 expres-
sion of approximately 40 % and 30 % after 24 
and 48 h reverse transfection with siCCR6 in 
HuCCT1, respectively (Figure 3c). The 
knockdown efficiency in TFK-1 was < 20 % 
(data not shown), therefore, HuCCT1 was se-
lected for CCR6 knockdown assay and related 
functional study. 
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Delayed wound closure and decreased cell 
migration in siCCR6 transfected HuCCT1  
To examine the role of CCL20/CCR6 sig-
naling in cell migration and proliferation, 
wound healing assay was performed in 
siCCR6 transfected HuCCT1. Compared to 
siNeg transfected cells, two-fold slower 
wound closure was observed in siCCR6 trans-
fected HuCCT1 (Figure 3d). MTS assay was 
performed to determine the effect of siCCR6 
on cell proliferation, there was no significant 
difference in proliferation rate between the 
siCCR6 and siNeg transfected HuCCT1 
(Supplementary Figure 2). Nevertheless, we 
could confirm the effect of siCCR6 on cell 
migration ability through transwell assay in 
which the number of migrated cells decreased 
significantly (p < 0.05) compared to siNeg 
transfected HuCCT1 (Figure 4a and b). 
Therefore, the EMT markers, E-cad and N-
cad, were further analyzed. Although the dif-
ference in E-cad expression was not observed, 
N-cad expression in siCCR6 transfected cells 
was slightly decreased suggesting the partial 
contribution of CCL20/CCR6 signaling in 
cell migration through EMT process 
(Figure 4c and d). We also analyzed the mi-
gration ability in rCCL20 treated HuCCT1, 
however, only slightly increased in the num-
ber of migrated cells could be observed 
(Supplementary Figure 3). 
 
 
Figure 3: mRNA and protein expression of CCL20 and CCR6, and the effect of CCR6 knockdown on 
wound healing ability in CCA cell lines. a) Real-time RT-PCR for CCL20 (gray bar) and CCR6 (black 
bar) in HuCCT1 and TFK-1. b) Baseline expression of E-cad and N-cad in HuCCT1 and TFK-1. c) 
Representative Western blot assays in 24 and 48 h siNeg and siCCR6 transfected HuCCT1. Relative 
protein expression from 3 independent assays was shown below the corresponding lane. d) Wound 
healing assay in siNeg and siCCR6 transfected HuCCT1. Image (40X) was recorded at indicated time 
points, the yellow line highlighted the wound closure area (left). Graph shows mean + SE for relative 
wound closure area from 3 independent assays in siNeg (circle) and siCCR6 (square) transfected cells 
(right). 
EXCLI Journal 2020;19:154-166 – ISSN 1611-2156 
Received: October 16, 2019, accepted: January 14, 2020, published: January 20, 2020 
 
 
162 
 
Figure 4: Effect of CCR6 knockdown on cell migration and EMT process in HuCCT1. a) The repre-
sentative image of the transwell membrane. The relative number of migrated cells from three independ-
ent assays were shown in b), * indicates p<0.05. c) Western blot analysis for CCR6, N-cad, E-cad, α-
tubulin, and β-actin. Relative protein expression from three independent Western blot assays was shown 
in d), * indicates p<0.05. 
 
 
rCCL20 induces cell migration through 
EMT process in TFK-1 
To avoid the effect of high constitutive 
CCL20 expression, we performed rCCL20 
treatment and employed transwell assay to de-
termine its effect on cell migration in TFK-1. 
Here we verified that the presence of rCCL20 
in the lower chamber of the transwell plate 
substantially increases the number of mi-
grated cells (Figure 5a and b). In addition, the 
increase in N-cad expression was observed in 
rCCL20 treated cells suggesting its effect on 
EMT process (Figure 5c and d). 
 
DISCUSSION 
Transcriptional profiling is an important 
resource for the development of precision 
medicine. Recent advances in technology, bi-
oinformatics, as well as the accumulation of 
data in public repository lead to better insight 
into disease biology and eventually result in a 
more effective diagnosis and treatment ap-
proach. While RNA sequencing is more in-
sightful, its number in CCA is still too small, 
so many integrative or meta-analyses have 
been performed mainly on microarray data. In 
this study, we not only employed a data-
driven approach to identify a novel biomarker 
but also performed a functional validation to 
confirm its potential utility for CCA manage-
ment. Recently Zhong et al. (2018) have re-
ported a similar integrative analysis of 7 mi-
croarray datasets. The additional 2 datasets 
were not included in our selection because the 
proportion of normal tissues in their studies 
was lower than 10 %. The analysis approach 
is another difference between Zhong’s and 
our study. The variation 
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Figure 5: The effect of rCCL20 treatment on cell migration and EMT process in TFK-1. Cells were 
cultured in medium containing 5%FBS with or without 100 ng/ml rCCL20. a) The representative images 
at 10X (top) and 40X (bottom) magnification of the transwell membrane. The relative number of migrated 
cells from three independent assays were shown in b. c) Western blot analysis for E-cad, N-cad, and -
tubulin (loading control). Relative protein expression from three independent western blot assays was 
shown in d. 
 
 
in samples and technology platforms was our 
major concern. Accordingly, we performed 
differential expression analysis separately in 
each dataset before combining them. We then 
selected transcripts that show similar expres-
sion pattern across all datasets. This approach 
may not retain all DEGs but assure the con-
sistency across multiple studies. To the best 
of our knowledge, our work is the first study 
demonstrating the role of CCL20/CCR6 in 
CCA. Nevertheless, the more comprehensive 
functional study in CCA is still needed be-
cause its role in other cancers is unclear and 
limited.  
Although, some previous studies have re-
ported that there is decrease in cell prolifera-
tion in cancer cell lines during EMT process 
(Kapur et al., 2016; Liu et al., 2017), while as 
others have found that there is no effect on 
cell (Vongsa et al., 2009; Boyle et al., 2015). 
From the results, our finding is in accordance 
with later group. Such variation may be asso-
ciated with time, characteristics of cell lines, 
and cell culture condition.  
We demonstrated the effect of CCL20/ 
CCR6 on cell migration, probably through 
EMT process, in line with many studies. The 
difference in the pattern of E-cad and N-cad 
expressions in HuCCT1 and TFK-1 led us to 
consider the association between EMT mark-
ers and characteristics of these cell lines. 
Since, HuCCT1 was derived from a meta-
static CCA, we hypothesize that its condition 
may be more biased toward a mesenchymal 
state. Interestingly, we found the high consti-
tutive expression of N-cad and low expression 
of E-cad in this cell line (Figure 3b). This re-
sult was consistent with a previous report in 
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CCA (Lu et al., 2014). We further confirmed 
this association by limiting CCL20/CCR6 
signaling using siCCR6 transfection. Alt-
hough it was not statistically significant, 
knockdown of CCR6 likely resulted in a de-
crease in N-cad expression. In contrast to 
HuCCT1, TFK-1 had lower expression of 
CCL20 and N-cad but higher expression of E-
cad. Treatment with rCCL20 could increase 
the expression of N-cad confirming the con-
tribution of CCL20/CCR6 signaling in EMT 
process. However, we did not observe any 
changes in the expression of E-cad. Thus, it is 
necessary to find an optimum time point to 
determine changes in E-cad expression or in-
clude other markers to determine the EMT 
process. 
Although the primary role of CCL20 is in 
inflammation process, it also contributes to 
changes in microenvironment that promotes 
the growth and progression of tumor cells 
(Frick et al., 2016). The association between 
autocrine and paracrine mechanism of CCL20 
and patient’s prognosis has been reported in 
many cancer types (Rubie et al., 2010; 
Coperchini et al., 2016; Frick et al., 2016; 
Kapur et al., 2016; Marsigliante et al., 2016; 
Wang et al., 2016). In addition, metastasis in 
patients who received perioperative FOLFOX 
(the combination of oxaliplatin, fluorouracil 
and leucovorin) chemotherapy was associated 
with CCL20/CCR6 over-expression (Rubie et 
al., 2011). Disruption of CCL20/CCR6 sig-
naling would therefore be an alternative ap-
proach for cancer treatment. Interestingly, 
GSK3050002, a neutralizing antibody to 
CCL20, is available and a clinical trial has 
shown that it is safe to use in human subjects 
(Bouma et al., 2017). Although CCR6-tar-
geted treatments are still under development, 
it is another promising approach for modulat-
ing CCL20/CCR6 signaling (Robert et al., 
2017). Conceivably, CCL20/CCR6 targeting 
is a feasible approach that could be useful in 
the treatment of CCA. 
 
CONCLUSION 
This study demonstrated the use of pub-
licly available high throughput data for the 
global identification of biomarker for CCA. 
CCL20, which showed a consistent expres-
sion pattern across multiple datasets, was val-
idated for its contribution to EMT-associated 
migration of CCA cell lines. This insight 
might be useful for the development of an al-
ternative approach for the treatment of CCA. 
Modulation of CCL20/CCR6 signaling is 
very promising based on the availability and 
the favorable effect of the anti-CCL20 anti-
body. Targeting these molecules can help in 
controlling the migration of cancer cells, es-
pecially at the advanced stages of the disease, 
which is a major challenge for the manage-
ment of CCA and other cancer types. 
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